XML 16 R46.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Fair Value Measurement - Additional Information (Detail) | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Sep. 30, 2014 USD ($) | Sep. 30, 2014 Novozymes Biopharma DK A/S Sweden Ab Milestone Payments EUR (€) | Sep. 30, 2014 Novozymes Biopharma DK A/S Sweden Ab Milestone Payments EUR (€) | Sep. 30, 2014 Bio Flash Minimum USD ($) | Sep. 30, 2014 Bio Flash Minimum USD ($) | Sep. 30, 2014 Refine Technology, LLC USD ($) | Jun. 02, 2014 Refine Technology, LLC USD ($) | Jun. 02, 2014 Refine Technology, LLC Milestone Payments USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |  |  |  |  |  |  |  |
Fair value of other assets | $ 0 |  |  |  |  |  |  |
Fair value of other liabilities | 0 |  |  |  |  |  |  |
Payment made | 1,246,348 | 850,000 | 850,000 |  |  |  |  |
Royalty payment |  |  |  | 80,000 | 80,000 |  |  |
Additional contingent consideration accrued |  |  |  |  |  | $ 1,370,000 | $ 1,370,000 | $ 1,400,000

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph b -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Fair value portion of other assets. + References No definition available. + Details
Name: | us-gaap_OtherAssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fair value portion of other liabilities. + References No definition available. + Details
Name: | us-gaap_OtherLiabilitiesFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of cash paid for royalties during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585 + Details
Name: | us-gaap_PaymentsForRoyalties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration